82 related articles for article (PubMed ID: 10121421)
21. Evolution of recombinant human erythropoietin usage in clinical practice in the United States. Is there an optimal way to use rHuEPO?
Besarab A; McCrea JB
ASAIO J; 1993; 39(1):11-8. PubMed ID: 8439674
[No Abstract] [Full Text] [Related]
22. Efficacy of intravenous methoxy polyethylene glycol-epoetin beta administered every 2 weeks compared with epoetin administered 3 times weekly in patients treated by hemodialysis or peritoneal dialysis: a randomized trial.
Klinger M; Arias M; Vargemezis V; Besarab A; Sulowicz W; Gerntholtz T; Ciechanowski K; Dougherty FC; Beyer U
Am J Kidney Dis; 2007 Dec; 50(6):989-1000. PubMed ID: 18037099
[TBL] [Abstract][Full Text] [Related]
23. Center effects in anemia management of dialysis patients.
Fink JC; Hsu VD; Zhan M; Walker LD; Mullins CD; Jones-Burton C; Langenberg P; Seliger SL
J Am Soc Nephrol; 2007 Feb; 18(2):646-53. PubMed ID: 17229911
[TBL] [Abstract][Full Text] [Related]
24. Once-every-2-weeks and once-weekly epoetin beta regimens: equivalency in hemodialyzed patients.
Mircescu G; Gârneată L; Ciocâlteu A; Golea O; Gherman-Căprioară M; Capsa D; Mota E; Gusbeth-Tatomir P; Ghenu A; Bălută S; Constantinovici N; Covic AC
Am J Kidney Dis; 2006 Sep; 48(3):445-55. PubMed ID: 16931218
[TBL] [Abstract][Full Text] [Related]
25. Is it time to reconsider subcutaneous administration of epoetin?
Patel TV; Robinson K; Singh AK
Nephrol News Issues; 2007 Oct; 21(11):57, 59, 63-4 passim. PubMed ID: 17970510
[TBL] [Abstract][Full Text] [Related]
26. Safety and tolerability of a multidose formulation of epoetin beta in dialysis patients. Collaborative Study Group.
Raftery MJ; Auinger M; Hertlová M
Clin Nephrol; 2000 Sep; 54(3):240-5. PubMed ID: 11020023
[TBL] [Abstract][Full Text] [Related]
27. Clinical benefits of epoetin alfa (Eprex) 10,000 units subcutaneously thrice weekly in Thai cancer patients with anemia receiving chemotherapy.
Voravud N; Sriuranpong V
J Med Assoc Thai; 2005 May; 88(5):607-12. PubMed ID: 16149676
[TBL] [Abstract][Full Text] [Related]
28. [Can anemia be corrected in hemodialysis patients with thalassaemia minor? ].
Di Iorio B; Guastaferro P; Gironda A; Marano V; Morrongiello L; Cillo N; Zito B; Nigro F; Frieri A; Rubino R; Bellizzi V
G Ital Nefrol; 2002; 19(5):552-9. PubMed ID: 12439845
[TBL] [Abstract][Full Text] [Related]
29. Effects of erythropoietin on strength and functional status of patients on hemodialysis.
Guthrie M; Cardenas D; Eschbach JW; Haley NR; Robertson HT; Evans RW
Clin Nephrol; 1993 Feb; 39(2):97-102. PubMed ID: 8448925
[TBL] [Abstract][Full Text] [Related]
30. Epoetin-beta (Recormon-Roche) in the treatment of renal anemia in patients with chronic renal failure.
Tilkian EE; Tzekov VD; Pandeva SM; Kumchev EP; Nikolov DG; Dimitrakov JD; Dimitrakov DD
Folia Med (Plovdiv); 2000; 42(3):11-5. PubMed ID: 11347329
[TBL] [Abstract][Full Text] [Related]
31. Anemia and erythropoietin in hemodialysis and continuous ambulatory peritoneal dialysis.
Korbet SM
Kidney Int Suppl; 1993 Feb; 40():S111-9. PubMed ID: 8445832
[No Abstract] [Full Text] [Related]
32. [Methoxy polyethylene glycol epoetin beta].
Taéron C
Rev Infirm; 2010 Apr; (159):47-9. PubMed ID: 20432857
[No Abstract] [Full Text] [Related]
33. A system for monitoring and dispensing epoetin.
Cohen MR
Hosp Pharm; 1990 Aug; 25(8):745-6. PubMed ID: 10105708
[TBL] [Abstract][Full Text] [Related]
34. Case management of the anemic patient. Epoetin alfa: focus on reimbursement.
Roe WI
ANNA J; 1992 Apr; 19(2):198-9. PubMed ID: 1586234
[TBL] [Abstract][Full Text] [Related]
35. Clinical and economic evaluation of an evidence-based institutional epoetin-utilization management program.
Buckley MS; Kane-Gill SL; Patel SA
Clin Ther; 2013 Mar; 35(3):294-302. PubMed ID: 23465799
[TBL] [Abstract][Full Text] [Related]
36. Epoetin alfa in anaemic children or adolescents on regular dialysis.
Bianchetti MG; Hämmerli I; Roduit C; Neuhaus TJ; Leumann EP; Oetliker OH
Eur J Pediatr; 1991 May; 150(7):509-12. PubMed ID: 1915505
[TBL] [Abstract][Full Text] [Related]
37. A comparison of the costs and benefits of recombinant human erythropoietin (epoetin) in the treatment of chronic renal failure in 5 European countries.
Leese B; Hutton J; Maynard A
Pharmacoeconomics; 1992 May; 1(5):346-56. PubMed ID: 10146999
[TBL] [Abstract][Full Text] [Related]
38. Cost analysis of an intravenous to subcutaneous epoetin α conversion.
Wazny LD; Raymond CB; Sood AR; Eng A; Verrelli M
Am J Nephrol; 2013; 38(6):496-500. PubMed ID: 24334854
[TBL] [Abstract][Full Text] [Related]
39. Trends in anemia treatment with erythropoietin usage and patient outcomes.
Collins AJ; Ma JZ; Xia A; Ebben J
Am J Kidney Dis; 1998 Dec; 32(6 Suppl 4):S133-41. PubMed ID: 9892380
[TBL] [Abstract][Full Text] [Related]
40. Blood pressure in hemodialysis patients during amelioration of anemia with erythropoietin.
Abraham PA; Macres MG
J Am Soc Nephrol; 1991 Oct; 2(4):927-36. PubMed ID: 1751794
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
